David Pidduck

CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth

MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY

Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method

MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY

Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil

MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report

MediPharm Settles Commercial Agreement Dispute With Tilray's Hexo For $9M

David Pidduck Recent News

Cannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The Details

Cannabinoid-focused pharmaceutical company MediPharm Labs Corp.

MediPharm Labs Corp. Q1 Revenue Grows 20% YoY, Achieves First Quarter Of Positive Adjusted EBITDA

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) announced financial results for Q1 2023, revealing EBITDA growth over the past two years and a significant reduction in losses to CA$2.1 million.

MediPharm Labs Begins Restructuring Following Acquisition Of VIVO, Reduces Non-Direct Labor Workforce By ~30%

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX:LABS) (FSE:MLZ) provided an update on progress made on the integration of VIVO Cannabis Inc.'s (OTCQB: VVCIF) operations follow

MediPharm Labs FY22 Revenue Grows Slightly To $16.3M

MediPharm Labs Corp. (TSX:LABS) (OTCQX: MEDIF) (FSE:MLZ) FY 2022 revenue was CA$22.1 million ($16.3 million), an increase of 1.8% compared to CA$21.7 million in FY 2021.

MediPharm Touts Strong Q3 Revenue Growth, Continues To Expand Internationally

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) announced on Monday its financial results for the three months ended Sept. 30, 2022.

MediPharm Labs Q2 Revenue Declines 14% YoY, Here Are The Details

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX:LABS) (FSE:MLZ) Q2 2022 revenue declined 14%, to CA$4.36 million ($3,37 million), compared to revenue of CA$5.07 million in Q2 2021.

MediPharm Labs Awarded Payment Of $9.8M By Ontario Court Of Justice

MediPharm Labs Corp.

MediPharm Labs Enters Into $4.68M Purchase Agreement For The Sale Of Australian Facility

MediPharm Labs Corp.

MediPharm Labs Q1 Revenue Slightly Drops, Here Are The Details

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) revenue decreased 11.24% to $4.88 million in Q1 2022 compared to $5.5 million in Q1 2021.